Skip to content

Monitoring the Response of Chemotherapy on Breast Cancer Tumor by Photon Migration Spectroscopy

Monitoring the Response of Chemotherapy on Breast Cancer Tumor by Photon Migration Spectroscopy

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00540852
Enrollment
77
Registered
2007-10-08
Start date
2002-06-30
Completion date
2011-01-31
Last updated
2022-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

Breast cancer receiving chemotherapy

Brief summary

Optimal management of patients with locally advanced breast cancer remains a complex therapeutic problem. Newly diagnosed breast cancers in the United States with a higher incidence in medically underserved areas. The optimal intensity and duration of neoadjuvant chemotherapy still remains controversial due to the difficulty of evaluating response to therapy. The goal would be to prevent over and under treatment of patients with neoadjuvant chemotherapy.

Detailed description

The Researcher developed a diagnostic device called Diffuse Optical Spectroscopy Imaging is a non-invasive optical technique that utilizes intensity-modulated, near-infrared light to quantitatively measure optical properties in thick tissues. Diffuse Optical Spectroscopy Imaging can images tissue hemoglobin , oxygen saturation, blood volume fraction, water content, fat content and cellular structure. The measurements provide quantitative optical property values that reflect changes in tissue perfusion, oxygen consumption, and cell/matrix development. There is no therapeutic benefit to the subject, especially none that might influence the indication for the diagnostic procedure as indicated. However, information obtained may lead to a new form of non-invasive imaging for the early detection of breast cancer.

Interventions

Diffuse Optical Spectroscopy Imaging

Sponsors

Beckman Laser Institute University of California Irvine
CollaboratorOTHER
Chao Family Comprehensive Cancer Center
CollaboratorOTHER
University of California, Irvine
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DEVICE_FEASIBILITY

Eligibility

Sex/Gender
FEMALE
Age
21 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Female non-pregnant and age greater than or equal to 21 years old but less than 75 years old * Diagnosed with breast cancer and will be receiving neoadjuvant chemotherapy

Exclusion criteria

* Female pregnant and age less than 21 years old and have no diagnosis of breast cancer

Design outcomes

Primary

MeasureTime frameDescription
Diagnostic tool12 weeksDiffuse Optical Spectroscopy Imaging Breast Cancer Tumor in the response of Chemotherapy

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026